Market Size of Tetanus Toxoid Vaccine Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Tetanus Toxoid Vaccine Market Analysis
The tetanus toxoid vaccine market is expected to register a CAGR of 4.8% during the forecast period.
The tetanus toxoid vaccine market was significantly impacted by COVID-19 during the initial phases since immunization programs were delayed due to the lockdown, and many countries experienced a shortage of vaccines. As per an article published in May 2022 in the Obstetrics and Gynaecology journal, during the second quarter of the pandemic, when many prenatal visits were done via telemedicine, patients were 1.3 times more likely not to receive Tdap vaccination (54%). Additionally, according to an article published in the Frontier Journal in October 2021, vaccination against diphtheria or tetanus was linked to less severe COVID-19 symptoms. By stimulating the immune system, these vaccinations may protect against severe COVID-19 symptoms. Currently, the market is anticipated to witness growth due to the rise in vaccination and immunization by the government, growth in research and development for tetanus vaccines, and their combination.
Tetanus, also known as lockjaw disease, is a non-communicable serious disease caused by a bacterial toxin that affects the nervous system, leading to painful muscle contractions, particularly the jaw and neck muscles. It is caused by Clostridium tetani (C. tetani) found in human and animal feces, soil, and street dust. Different vaccines include protection against tetanus DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine. For instance, according to the WHO, 9,707 cases of tetanus were reported in 2021 globally. As per the same source, 4,140 cases of neonatal tetanus were reported in 2021.
Furthermore, as per a Global Health Policy January 2022 report, through June 30, 2021, cumulative U.S. contributions made up 13% of all funds received by Gavi, an independent public-private partnership and multilateral funding mechanism that aims to expand global access to the use of vaccines, particularly among vulnerable children (nearly USD 2.8 billion out of more than USD 21 billion). Over time, U.S. donations have increased, recently reaching an annual level of USD 290 million.
Moreover, product launches and collaborations to develop tetanus vaccination and immunization are other driving factors of the tetanus toxoid vaccine market. For instance, in March 2021, Stablepharma collaborated with the European vaccine manufacturer BB-NCIPD (Bul Bio) to develop a thermally stable version of the tetanus-diphtheria (Td) vaccine using the patented StablevaX formulation and device.
On the other hand, the side effects associated with the toxoid vaccine restrain the market growth over the forecast period.
